The Follow-up of Patients with Severe Acne Vulgaris Treated with Systemic Isotretinoin

Czech version

Authors: Z. Nevoralová
Authors‘ workplace: Kožní oddělení, Nemocnice v Jihlavě, p. o., prim. MUDr. Štefan Dubáň
Published in: Čes-slov Derm, 85, 2010, No. 4, p. 198-208
Category: Clinical and laboratory Research

Overview

The aim of the follow-up was to evaluate safety of the treatment, the treatment possibilities in patients with other concomitant diseases and possibility of physical load in treated sportsmen. Following parameters were analyzed: sex and age, localization and type of acne, concomitant diseases, signs of depression and sport activities before treatment; all side effects including laboratory abnormalities, control of concomitant diseases, signs of depression and sport activities during the treatment. Finally, the therapeutic effect was evaluated. The total number of treated and followed patients was 100. Concomitant diseases and laboratory abnormalities before treament were present in 51 % of patients. Intensive sports activities were mentioned by 51 % of males and 10 % of females. Only mild side effects were observed during the treatment. In addition to previously known adverse effects, constipation and lower extremities cramps were newly recorded. No case of depression caused by isotretinoin was observed. Treatment results were excellent in 97 % of cases. The follow-up showed high efficacy and safety of isotretinoin. The treatment was successful also in patients with concomitant internal diseases and laboratory abnormalities. Adequate sports activities during therapy did not influenced the treatment efficacy and safety.

Key words:
acne – systemic isotretinoin – side effects

Sources

1. ALCALAY, J., LANDAU, M., ZUCKER, A.: Analysis of laboratory data in acne patients treated with isotretinoin: is there really a need to perform routine laboratory tests? J Dermatol Treat, 2001, 12 (1), p. 9-12.

2. ALTMAN, S., ALTMAN, LJ., ALTMAN, JS.: A Proposed Set of New Guidelines for Routine Blood Tests during Isotretinoin Therapy for Acne vulgaris. Dermatology, 2002, 204 (3), p. 232-235.

3. BACHMEYER, C., CHAROUD, A., TURC, Y. et al.: Isotretinoin-Induced Bilateral Sacroilitis. Dermatology, 2003, 206, p. 285-286.

4. BRUNO, NP., BEACHAM, BE., BURNETT, JP.: Adverse Effects of Isotretinoin Therapy. Cutis, 1984, 33 (5), p. 484-487.

5. BUCHVALD, J.: Skúsenosti s isotretinoinom (Roaccutane) v liečbe akné a niektorých iných dermatóz. Čs Derm, 1985, 60 (4), s. 225-232.

6. CAMISA, C.: Acute arthritis during isotretinoin treatment for acne. J Am Acad Dermatol, 1986, 15 (5), s. 1061-1062.

7. COOPER, AJ. et al.: Treatment of acne with isotretinoin: Reccomendations based on Australian experience. Australas J Dermatol, 2003, 44, p. 97-105.

8. CUNLIFFE, WJ.: Side effects of acne therapy. In CUNLIFFE, W., J. Acne. London: Martin Dunitz Ltd., 1. vydání, 1989, p. 288-324.

9. CUNLIFFE, WJ. et al.: Roaccutane Treatment Guidelines: Results of an International Survey. Dermatology, 1997, 194, p. 351-357.

10. CUNLIFFE, WJ.: The difficult acne patient. Acta Dermatovenerol Croat, 2001, 9 (3), p. 183-195.

11. CUNLIFFE, WJ., GOLLNICK, HP.: Acne. Diagnosis and management.. In CUNLIFFE, WJ., GOLLNICK, HP. Acne. London: Martin Dunitz Ltd. 2001, p. 166.

12. DRENO, B., CHOSIDOW, O.: Isotretinoin and psychiatric effects: facts and hypothesis. Expert Rev Dermatol, 2008, 6, p. 711-720.

13. ELLIS, CHN., KRACH, KJ.: Uses and complications of isotretinoin therapy. J Am Acad Dermatol, 2001, 45 (5), p. S150-S157.

14. FIALLO, P.: Severe Acute Myopathy Induced by Isotretinoin. Arch Dermatol, 1996, 132, p. 1521-1522.

15. FISCHER, DA.: Exercise-induced bronchoconstriction related to isotretinoin therapy. J Am Acad Dermatol, 1985, 13 (3), p. 524.

16. FRAUNFELDER, FT., FRAUNFELDER, FW., EDWARDS, R.: Ocular Side Effects Possibly Associated with Isotretinoin Usage. Am J Ophthalmol, 2001, 132 (3), p. 299-305.

17. GODFREY, KM., JAMES, MP.: Treatment of severe acne with isotretinoin in patients with inflammatory bowel disease. Br J Dermatol, 1990, 123, p. 653-655.

18. GOLLNICK, H., P., CUNLIFFE, WJ.: Management of acne. A report from a global aliance to improve outcomes in acne. J Am Acad Dermatol, 2003, 49, p. 1-38.

19. HANSON, N., LEACHMAN, S.: Safety Issues in Isotretinoin Therapy. Semin Cutan Med Surg, 2001, 20 (3), p. 166-183.

20. HODGKISS-HARLOW CJ., EICHENFIELD, LF., DOHIL, MA.: Safety and adverse effects of isotretinoin in pediatric dermatology clinical setting (abstract). In CD of

21. HUGHES, RA.: Arthritis Precipitated by Isotretinoin Treatment for Acne Vulgaris. J Rheumatol, 1993, 20 (7), p. 1241-1242.

22. HULL, MS., CUNLIFFE, WJ.: The safety of isotretinoin in patients with acne and systemic diseases. J Dermatol Treat, 1989, 1, p. 35-37.

23. CHARAKIRA, A., MOUSER, PE., CHU, AC.: Safety and side effects of the acne drug, oral isotretinoin. Ashley Publications Ltd ISSN 1474-0338, 2004, p. 119-125.

24. CHRISTMAS, T.: Roaccutane and menorrhagia. J Am Acad Dermatol, 1988, 18 (3), p. 576-577.

25. KAPLAN, G., HAETTICH, B.: Rheumatological symptoms due to retinoids. Baillieres Clin Rheumatol, 1991, 5 (1), p. 77-99.

26. KAPUR, N.: Exacerbation of asthma by isotretinoin. Br J Dermatol, 2000, 142 (2), p. 370-393.

27. KAYMAK, Y.: Creatine phosphokinase values during isotretinoin treatment for acne. Int J Dermatol, 2008, 47 (4), p. 398-401.

28. KWON, HJ., LEE, JY., CHO, BK. et al.: Menstrual irregularity during isotretinoin treatment. J Eur Acad Dermatol Venereol, 2007, 21, p. 562-563.

29. LAYTON, AM., STAINFORTH, JM., CUNLIFFE, WJ.: Ten years‘ experience of oral isotretinoin for the treatment of acne vulgaris. J Dermatol Treat, 1993, 4 (Suppl.2), S2-S5.

30. LAYTON, AM., DRENO, B., GOLLNICK, HP. et al.: A review of European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol, 2006, 7, p. 773-776.

31. LE GAL, F., A., PAUWELS, CH.: Maladie de Gilbert et isotrétinoine, Ann Dermatol Venereol, 1997, 124, p. 463-466.

32. LEHUCHER-CEYRAC, D., WEBER-BUISSET, MJ.: Isotretinoin and Acne in Practice: A Prospective Analysis of 188 Cases over 9 Years. Dermatology, 1993, 186 (2), p. 123-128.

33. LEYDEN, JJ.: The role of isotretinoin in the treatment of acne: personal observationes. J Am Acad Dermatol, 1998, 39, p. S45-S49.

34. LEYDEN, JJ., MC GINLEY, KJ., FOGLIA, AN.: Qualitative and quantitative changes in cutaneous bacteria associated with systemic isotretinoin therapy for acne conglobata. J Invest Dermatol, 1986, 86 (4), p. 390-393.

35. KARLSSON, T., VAHLQUIST, A., KEDISHVILI, N. et al.: 13-Cis retinoic acid competitevely inhibits 3 alpha-hydroxysteroid oxidation by retinol dehydrogenace RoDH-4: a mechanism for its anti-androgenetic effects in sebaceous glands? Biochem Biophys Res Commun, 2003, 303(1), p. 273-278.

36. LEHUCHER-CEYRAC, D.: Acute Arthritis after Isotretinoin. Dermatology, 1999, 198, p. 406-407.

37. MARQUELING, AL., ZANNE, LT.: Depression and suicidal behavior in acne patients treated with isotretinoin: a systemic review. Sem Cut Med Surg, 2005, 24(2), p. 92-102.

38. MARTIN, P., MANLEY, PN., DEPEW, WT. et al.: Isotretinoin-Associated Proctosigmoiditis. Gastroenterology, 1987, 93 (3), p. 606-609.

39. MATSUOKA, LY., WORTSMAN, J., PEPPER, JJ.: Acute arthritis during isotretinoin 40. MC LANE, J.: Analysis of common side effects of isotretinoin. J Am Acad Dermatol, 2001, 45 (5), p. S188-S194.

41. NELSON, AM., GILLILAND, KL., CONG, Z.: 13-Cis retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol, 2006, 126(10), p. 2178-2189.

42. PLEWIG, G., GOLLNICK, HP., MEIGEL, W. et al.: 13-Cis retinoic acid in the oral therapy of acne conglobata. Results of a multi-center study. Hautarzt, 1981, 32(12), p. 634-646.

43. PLEWIG, G., KLIGMAN, AM.: Acne and Rosacea. 3rd Completely Revised and Enlarged Edition. Berlin-Heidelberg-New York: Springer-Verlag. 2000, p. 245-247, 577-730.

44. RADMANESH, M.: Anal fissure, rectal bleeding and proctitis as complications of systemic isotretinoin therapy: report of two cases. J Eur Acad Dermatol Venereol, 2006, 20, p. 1394.

45. RENIERS, DE., HOWARD, JM.: Isotretinoin-Induced Inflammatory Bowel Disease in an Adolescent. The Annals of Pharmacotherapy, 2001, 35, p. 1214-1216.

46. RULCOVÁ, J.: Zhodnocení průběhu a výsledků léčby acne vulgaris izotretinoinem. Čes-slov Derm, 2001, 76 (1), s. 25-31.

47. RULCOVÁ, J., ZÁHEJSKÝ, J.: Roaccutane v terapii těžších forem akné. Čs Derm, 1986, 61(6), s. 369-374.

48. SABROE, RA., STAUGTON, RCD., BUNKER, CB.: Bronchospasm induced by isotretinoin. Br J Dermatol, 1996, 312 (7035), p. 886.

49. SCHLEICHER, SM.: Oral isotretinoin and inflammatory bowel disease. J Am Acad Dermatol, 1985, 13(5), s. 834-835.

50. STAELS, B.: Regulation of lipid and lipoprotein mechanism by retinoids. J Am Acad Dermatol, 2001, 45, p. S158-S167.

51. SUARÉZ CJF., GARCIA, MV., BECERRA MP. e col.: Pueden ser tratados con isotretinoín los pacientes con acné y síndrome de Gilbert? Rev Esp Enf Digest, 1996, 8, p. 584-585.

52. VOHRADNÍKOVÁ, O. et al.: Léčba těžkých forem akné Roaccutanem. Čs Derm, 1988, 63 (6), s. 396-401.

53. WANG, JI., JACKSON, TL., KAPLAN DL.: Isotretinoin-associated normalisation of hyperbilirubinemia in patients with Gilbert´s syndrome. J Am Acad Dermatol, 1995, 32, p. 136-138.

54. ZANE, LT., LEYDEN, WA., MARQUELING, AL. et al.: A Polulation-Based Analysis of Laboratory Abnormalities During Isotretinoin Therapy for Acne Vulgaris. Arch Dermatol, 2006, 142, p. 1016-1022.

Labels

Dermatology & STDs Paediatric dermatology & STDs

Current Developments and New Treatment Options in the Therapy of Melanoma

Nystatin – Newly Available Drug for Extemporaneous Preparation

Commentary to the Guidelines of The European Dermatology Forum on the Systemic Treatment of Psoriasis Vulgaris

Pseudoxanthoma elasticum

Article was published in

Czech-Slovak Dermatology

2010 Issue 4